The patient - Who may benefit from CEVENTRIX™? ​

A study with propionate (Duscha et al, 2020) has been performed with both RRMS, SPMS, and PPMS showing benefits of propionate with all subtypes.

In the study by Duscha et al, reduced levels of propionate in stool and serum compared to healthy control subjects was found in all subtypes of MS (RRMS, SPMS, and PPMS), including also the de novo cohort. Supplementation with propionate restored stool and serum levels of propionate in all subgroups by two weeks. Subsequently, the number and function of Treg cells was restored, and TH17 was reduced towards normal levels in all subgroups.

The changes in Treg numbers and function appeared to be independent of variations in background medications, as did the observed clinical benefits. These results though should be interpreted with care as numbers are often too small for meaningful statistical analyses. Please see Duscha et al 2020 for more information.

No serious adverse events were reported with 3 years of use and less than 5% of subjects had mild adverse events. The reported events were abdominal distension, flatulence, and nausea.

CEVENTRIX™ can be used for dietary management of all subgroups of MS, irrespective of background medication.